167 related articles for article (PubMed ID: 35312904)
1. Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.
Asano K; Yamashita Y; Ono T; Natsumeda M; Beppu T; Matsuda K; Ichikawa M; Kanamori M; Matsuzaka M; Kurose A; Fumoto T; Saito K; Sonoda Y; Ogasawara K; Fujii Y; Shimizu H; Ohkuma H; Kitanaka C; Kayama T; Tominaga T
Brain Tumor Pathol; 2022 Jul; 39(3):139-150. PubMed ID: 35312904
[TBL] [Abstract][Full Text] [Related]
2. The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.
Asano K; Yamashita Y; Ono T; Natsumeda M; Beppu T; Matsuda K; Ichikawa M; Kanamori M; Matsuzaka M; Kurose A; Saito K; Sonoda Y; Ogasawara K; Fujii Y; Shimizu H; Ohkuma H; Kitanaka C; Kayama T; Tominaga T
Int J Clin Oncol; 2022 Jan; 27(1):77-94. PubMed ID: 34637053
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Lu CH; Lee KF; Chen CC; Chen YY; Huang CE; Tsai PS; Tsou HY; Chou HJ; Chen MF; Chen PT; Lee KD; Lung J
Jpn J Clin Oncol; 2014 Dec; 44(12):1164-71. PubMed ID: 25320341
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
7. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.
Okamoto A; Yanada M; Miura H; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
Cancer Sci; 2015 Nov; 106(11):1576-81. PubMed ID: 26353084
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
9. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
10. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
Shen Z; Hu L; Yao M; He C; Liu Q; Wang F; Gu W; Wang Y; Dong M; Zhu T; Yin T; Li F; Jin Y; Huang S; Zhang H; Sang W;
Int J Cancer; 2022 Jan; 150(2):327-334. PubMed ID: 34520566
[TBL] [Abstract][Full Text] [Related]
11. [Different treatment regimens for primary central nervous system lymphoma:based on SEER database].
Yang CW; Ren XH; Jiang HH; Li MX; Zhao XZ; Zhu QH; Cui Y; Lin S
Zhonghua Wai Ke Za Zhi; 2021 Jan; 59(1):52-58. PubMed ID: 33412634
[No Abstract] [Full Text] [Related]
12. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
14. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
15. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
16. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.
Ohashi A; Kato S; Okamoto A; Inaguma Y; Satou A; Tsuzuki T; Emi N; Okamoto M; Nakamura S
Histopathology; 2017 Jul; 71(1):89-97. PubMed ID: 28231401
[TBL] [Abstract][Full Text] [Related]
18. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.
Hong JY; Hong ME; Choi MK; Kim YS; Chang W; Maeng CH; Park S; Lee SJ; Do IG; Jo JS; Jung SH; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2014 Jan; 25(1):182-8. PubMed ID: 24356628
[TBL] [Abstract][Full Text] [Related]
19. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients.
Asano N; Yamamoto K; Tamaru J; Oyama T; Ishida F; Ohshima K; Yoshino T; Nakamura N; Mori S; Yoshie O; Shimoyama Y; Morishima Y; Kinoshita T; Nakamura S
Blood; 2009 Mar; 113(12):2629-36. PubMed ID: 19075188
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]